The Association Between Folate and Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Xiaohong Zhang1,2,3, Guangyi Bao2,3, Debiao Liu2,3, Yu Yang2,3,4, Xuezhi Li2,3,4, Gaomei Cai5, Yan Liu2,3,4 and Yili Wu2,3,4*

1 College of Marine Life Sciences, Ocean University of China, Qingdao, China, 2 Shandong Key Laboratory of Behavioral Medicine, School of Mental Health, Jining Medical University, Jining, China, 3 Shandong Collaborative Innovation Center for Diagnosis, Treatment & Behavioral Interventions of Mental Disorders, Institute of Mental Health, Jining Medical University, Jining, China, 4 Center of Evidence-Based Medicine, Jining Medical University, Jining, China, 5 Department of Neurology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, China

Alzheimer’s disease (AD) is the most common type of neurodegenerative disease leading to dementia in the elderly. Increasing evidence indicates that folate plays an important role in the pathogenesis of AD. To investigate the role of folate deficiency/possible deficiency in the risk of AD and the beneficial effect of sufficient folate intake on the prevention of AD, a systematic review and meta-analysis were performed. The Web of Science, PubMed, CENTRAL, EBSCO, CNKI, CQVIP, and Wanfang databases were searched. The analysis of cross-sectional studies showed that the standardized mean difference (SMD) was −0.60 (95% confidence interval (CI): −0.65, −0.55), indicating that plasma/serum folate level is lower in AD patients than that in controls. Moreover, the combined odds ratio (OR) of case-control studies was 0.96 (95% CI: 0.93, 0.99), while the combined ORs were 0.86 (95% CI: 0.46, 1.26) and 1.94 (95% CI: 1.02, 2.86) in populations with normal levels of folate (≥13.5 nmol/L) and folate deficiency/possible deficiency (<13.5 nmol/L), respectively. In addition, the risk ratio (RR) of the cohort studies was 1.88 (95% CI: 1.20, 2.57) in populations with folate deficiency/possible deficiency. Furthermore, when the intake of folate was equal to or higher than the recommended daily allowance, the combined RR and hazard ratio (HR) were 0.44 (95% CI: 0.18, 0.71) and 0.76 (95% CI: 0.52, 0.99), respectively. These results indicate that folate deficiency/possible deficiency increases the risk for AD, while sufficient intake of folate is a protective factor against AD.

Keywords: Alzheimer’s disease, folate level, folate deficiency, sufficient folate intake, meta-analysis

INTRODUCTION

Alzheimer’s disease (AD) is the most common type of neurodegenerative disease leading to dementia in the elderly. A progressive memory loss and deterioration of other cognitive functions are the main clinical manifestations, while extraneuronal neuritic plaques, intraneuronal neurofibrillary tangles, and neuronal loss are the neuropathological hallmarks of AD (Hebert et al., 2013; Bakota and Brandt, 2016; Mantzavinos and Alexiou, 2017; Li et al., 2018). According to the age of onset, AD is classified into early-onset AD (EOAD) and late-onset AD (LOAD). Compared with EOAD (onset before age 65), LOAD (onset after age 65) accounts for 95% or more of AD cases (Alzheimer’s Association, 2012). With the rapid increase of the aging population worldwide, over
50 million people were living with dementia globally in 2019 and the number is said to increase to 152 million by 2050 (Alzheimer's Disease International, 2019). The total cost for dementia was about 1 trillion US dollars in 2019 and it will be doubled by 2030 (Alzheimer's Disease International, 2019). AD accounts for 60–80% of dementia. Preventing or delaying the onset of AD is a priority as there is no effective treatment for AD.

Increasing evidence has indicated that dietary patterns and nutrition are implicated in the pathogenesis of AD (Otaegui-Arrazola et al., 2014). Thus, healthy diet and the balance of nutrients including vitamins are key factors in AD prevention. For example, marginal vitamin A deficiency promotes Aβ generation, the major component of neuritic plaques, and subsequent cognitive deficits (Zeng et al., 2017). Increasing evidence suggests that folate, an essential vitamin, plays an important role in AD development (Hernandez et al., 2016; Tian et al., 2016; Robinson et al., 2018; Guo et al., 2019). The normal range of plasma/serum folate ranges from 13.5 nmol/L to 45.3 nmol/L. Folate deficiency and possible deficiency are defined when the level of plasma/serum folate is <6.8 nmol/L and 13.5 nmol/L, respectively (WHO, 2015). Previous studies showed that low folate level is not only associated with specific domains of cognitive functioning, e.g., episodic recall and recognition (Wahlin et al., 1996; Hassing et al., 1999; Nurk et al., 2005; De Lau et al., 2007), but also associated with all types of dementia, including vascular dementia and AD (Clarke et al., 1998; Eby et al., 1998; Morris, 2003; Zhuo et al., 2011; Douaud et al., 2013; Cascalheiro et al., 2015). In addition, folate/folic acid supplementation is beneficial to the improvement of cognitive functions in aged subjects and cases of mild cognitive impairment (Fioravanti et al., 1997; Morris, 2003; Durga et al., 2007; De Jager et al., 2012; Ma et al., 2019). Moreover, deprivation of folate increases tau phosphorylation, the major component of neurofibrillary tangles (Chan and Shea, 2006). However, there has not been a meta-analysis study to investigate the association between folate deficiency/possible deficiency and the risk of AD, as well as the beneficial effect of sufficient folate intake on the prevention of AD.

This study aims to investigate the role of folate deficiency/possible deficiency in the risk of AD and the beneficial effect of sufficient folate intake on the prevention of AD in addition to updating the association between plasma/serum folate levels and AD. We designed and performed this systematic review and meta-analysis to evaluate the difference of folate levels between AD patients and healthy controls, the association of folate deficiency/possible deficiency with AD risk, and the effect of sufficient folate intake on the prevention of AD.

**MATERIALS AND METHODS**

**Protocol and Registration**

This systematic review and meta-analysis were conducted in accordance with the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) (Stroup et al., 2000) statement published in 2009. The study protocol was developed before this review and was registered at PROSPERO with the registration number CRD42020173072.

**Search Strategy and Selection Criteria**

To find publications of the association between folate and AD, two authors independently performed a systematic literature search in four English databases (Web of Science, PubMed, CENTRAL, EBSCO), and three Chinese databases (CNKI, CQVIP, and Wanfangdata). Boolean search techniques were carried out in full text, i.e., (Folic acid OR Folate OR vitamin B9 OR Vitamin Bc OR pteroylglutamic acid OR R factor OR MTHFR OR methyltetrahydrofolate reductase) AND (dementia OR Alzheimer). In addition, the references of identified publications were also screened by two independent authors. Only studies on AD, not other types of dementia [e.g., vascular dementia (VAD)], were included for the systematic review and meta-analysis in this study although both “dementia” and “Alzheimer” were included in the search terms list in order to avoid missing any study related to AD. The searching process was completed on December 31, 2019.

**Inclusion and Exclusion Criteria**

The inclusion criteria were: (1) cross-sectional studies, case-control studies, or longitudinal studies with primary data collection; (2) studies conducted in the general population; (3) outcomes of individuals with AD were determined by clinicians’ diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria, the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria, the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria or pathological criteria; (4) studies that provided sufficient statistical data to calculate the combined effect sizes; and (5) studies in any language and publication period.

The following types of studies were excluded: (1) studies with non-primary data such as opinion articles, editorials, letters to the editor, and comments; (2) animal studies; (3) qualitative studies; (4) dissertations; and (5) studies that could not provide sufficient statistical data.

**Quality Evaluation and Data Extraction**

The Newcastle-Ottawa Scale (NOS, scores range from 0 to 9) was used to assess the quality and risk of bias (Stang, 2010). Studies with a NOS score of 6 or more were included for the meta-analysis. All discrepancies were resolved by discussion with a third author.

Two authors independently extracted the following data from all articles: first author’s name, publication year, country of survey, number of cases and controls, mean age of participants, the mean and standard deviation of folate or odds ratio (OR) or risk ratio (RR) or hazard ratio (HR) and their 95% confidence intervals (CI).

The standardized mean difference (SMD) is used as a summary statistic in meta-analysis when the studies all assess the same outcome, but measure it in a variety of ways. The SMD expresses the size of the intervention effect in each study relative to the between-participant variability in outcome measurements observed in that study (Cochrane Training, 2020). In the current study, SMD was used to calculate differences of mean folate levels.
between people who did and did not suffer from AD. SMD and corresponding 95% CIs of plasma/serum folate were calculated based on the sample size, mean, and SD. Median and range were also used to estimate mean and SD (Hozo et al., 2005). 95% CI was transformed from SD through the formula as follows: 95% CI = mean ± 1.96 SD. The 25th and 75th percentiles were transformed to SD through the following formula: SD = Norm IQR = (P75–P25) × 0.7413 (IQR: inter-quartile range; P75: 75th percentile; P25: 25th percentile). SMD < 0 represents a folate level that is lower in the AD group compared with that in the control group.

Measures of relative effect express the expected outcome in one group relative to that in the other. RR is the ratio of the risk of an event in the two groups, whereas OR is the ratio of the odds of an event. For both measures a value of 1 indicates that the estimated effects are the same for both interventions, while a value <1 might indicate a beneficial effect of an experimental intervention. The most appropriate way of summarizing time-to-event data is to use methods of survival analysis and express the intervention effect as a HR. Hazard is similar in notion to risk, but is subtly different in that it measures instantaneous risk and may change continuously (Cochrane Training, 2020). In the current study, OR, RR, and HR were used to indicate the beneficial effect (<1) or detrimental effect (>1) of different folate levels and amount of folate intake.

Data Synthesis and Statistical Analysis
All statistical analyses were performed using Stata 15.0. The pooled effect size (SMD/OR/RR/HR) and its 95% CI were reported. A two-sided p < 0.05 was considered statistically significant.

Different models were used based on heterogeneity tests. The heterogeneity of the included studies was evaluated using Higgins I² test. The random-effect model was used if I² > 50%, which was marked in the forest plots. The fixed-effect model was used if I² ≤ 50%, which was not marked in the forest plots.

Funnel plots and an Egger’s test were used to investigate the potential publication bias. The Egger’s test was only conducted when six or more studies were included.

Sensitivity Analysis
When the heterogeneity was high (I² > 50%), sensitivity analysis was conducted to evaluate the stability of the outcome. Sensitivity analysis was performed by excluding an individual study at one time. A two-sided p < 0.05 was considered statistically significant. The random-effect model was used. A subgroup meta-analysis was further conducted for the combined index of AD based on the level of plasma/serum folate and the daily intake of folate.

RESULTS
Characteristics of Included Studies
A total of 3,672 publications (including 3,370 in English and 302 in Chinese) related to AD in the general population were initially identified from the databases. Sixty-two publications were included in this systematic review and 59 of them were included for further meta-analysis (Figure 1). Fifty-six and three articles were published in English and Chinese, respectively. Forty publications only included cross-sectional studies and eight publications only included cohort studies, respectively. Ten publications included both cross-sectional and case-control studies, while one publication included both cross-sectional and cohort studies. The studies were conducted in European countries (33 publications), Asian countries (14 publications),

FIGURE 1 | Flow diagram of the process used to breakdown the retrieved publications into publications suitable for meta-analysis.
### Table 1: Summary of studies of folate levels (nM/L) among AD patients and healthy controls in 52 cross-sectional studies.

| References                          | Mean age (years) | Sample size | Folate levels (nM/L) (Mean ± SD) | Country               |
|-------------------------------------|------------------|-------------|----------------------------------|-----------------------|
|                                     | AD (years)       | Control     | AD (years)                       | Control              |
| Levitt and Karlinsky (1992)         | 68.4 ± 11.1      | 71.0 ± 9.9  | 40                                | 26                   |
| Parnetti et al. (1992)              | 62.7 ± 1.2       | 72.1 ± 1.4  | 52                                | 26                   |
| Regland et al. (1992)               | 64 ± 5           | 65 ± 7      | 23                                | 32                   |
| Abalan et al. (1996)                | 80.2 ± 5.7       | 78.9 ± 7.2  | 12                                | 12                   |
| Joosten et al. (1997)               | 82.8 ± 4.9       | 79 ± 5.9    | 52                                | 49                   |
| Clarke et al. (1998)                | 73.2 ± 8.6       | 72.8 ± 8.8  | 164                               | 108                  |
| Lebihuber et al. (2000)             | 74.8 ± 8.8       | 70.2 ± 8.8  | 19                                | 19                   |
| Ravaglia et al. (2001)              | 101 ± 2          | 103 ± 2     | 34                                | 39                   |
| Serot et al. (2001)                 | 75.9 ± 6.6       | 72.7 ± 7.02 | 30                                | 36                   |
| Bottiglieri et al. (2001)           | 71 ± 8.5         | 40.6 ± 14.6 | 48                                | 14                   |
| Postiglione et al. (2001)           | 68 ± 8           | 68 ± 7      | 74                                | 74                   |
| Hogervost and Smith (2002)          | 77 ± 8           | 76 ± 8      | 66                                | 62                   |
| Molloy et al. (2002)                | 77.2 ± 8.1       | 74.3 ± 7.6  | 83                                | 71                   |
| Selley et al. (2002)                | 77.4             | 78.4        | 27                                | 25                   |
| Religa et al. (2003)                | 74.2 ± 6.3       | 71.2 ± 6    | 99                                | 100                  |
| Galucci et al. (2004)               | 76.9 ± 6.8       | 76.9 ± 9.7  | 137                               | 42                   |
| Mizrahi et al. (2004)               | 79.1 ± 7.7       | 75.6 ± 8.5  | 74                                | 55                   |
| Quadri et al. (2004)                | 69.4 ± 5         | 68 ± 7      | 30                                | 30                   |
| Anello et al. (2004)                | 71.0 ± 6.6       | 69.5 ± 12.7 | 180                               | 181                  |
| Malaguarnera et al. (2004b)         | 72.6 ± 7.38      | 73.7 ± 4.20 | 22                                | 24                   |
| Malaguarnera et al. (2004a)         | 71.3 ± 8.0       | 73.6 ± 4.1  | 30                                | 30                   |
| Ravaglia et al. (2004)              | 86.7 ± 5.4       | 86.7 ± 5.9  | 51                                | 29                   |
| Izziray et al. (2005)               | 75.9 ± 8.7       | 70.3 ± 9.8  | 145                               | 88                   |
| Dominguez et al. (2005)             | 73.4 ± 5.4       | 73.9 ± 8.9  | 29                                | 19                   |
| Quadri et al. (2005)                | 78.9 ± 7.5       | 75.0 ± 8.5  | 111                               | 79                   |
| De Silva et al. (2005)              | 72 ± 6.8         | 70.5 ± 3.9  | 23                                | 21                   |
| Anberro et al. (2006)               | 67.7 ± 7.2       | 63.6 ± 9.6  | 32                                | 61                   |
| Liu and Chen (2008)                 | 69.2 ± 7.3       | 69.1 ± 7.9  | 31                                | 40                   |
| Lovati et al. (2007)                | 76.6 ± 7.5       | 67.6 ± 7.2  | 108                               | 76                   |
| Koseoglu and Karaman (2007)         | 78.3 ± 4.1       | 76.1 ± 3.9  | 51                                | 40                   |
| Hagnelius et al. (2008)             | 72.7 ± 10.1      | 64.1 ± 9.5  | 42                                | 73                   |
| Gaimberti et al. (2008)             | 78.45 ± 4.63     | 70.13 ± 3.01| 29                                | 23                   |
| Karimi et al. (2009)                | 75 ± 16          | 68 ± 8      | 51                                | 49                   |
| Villa et al. (2009)                 | 70.8 ± 7.8       | 74.7 ± 6.7  | 20                                | 18                   |
| Linnebank et al. (2010)             | 73 ± 8           | 62 ± 10     | 60                                | 60                   |
| Agarwal et al. (2010)               | 65.03 ± 2.1      | 48.65 ± 1.2 | 32                                | 127                  |
| Morillas-Ruiz et al. (2010)         | 76.5 ± 5.5       | 79 ± 4      | 52                                | 48                   |
| Faux et al. (2011)                  | 78.4 ± 7.7       | 70 ± 7      | 205                               | 760                  |
| Art et al. (2012)                   | 73.5 ± 7.4       | 50.0 ± 16.8 | 51                                | 98                   |
| Almeida et al. (2011)               | 70 ± 5.93        | 67 ± 4.45   | 40                                | 49                   |
| Czarzpoli et al. (2012)             | 74.8 ± 6.6       | 71.4 ± 6.6  | 204                               | 99                   |
| Kim et al. (2013)                   | 79.4 ± 6.8       | 71.4 ± 6.6  | 100                               | 121                  |
| Kim and Lee (2014)                  | 76.73 ± 7.63     | 75.86 ± 5.74| 77                                | 37                   |
| Morsorri et al. (2014)              | 66.3 ± 8.9       | 63.8 ± 8.2  | 80                                | 120                  |
| Li et al. (2014)                    | 76.96 ± 7.58     | 75.14 ± 12.98| 126                               | 120                  |
| Chen et al. (2015)                  | 67.6 ± 7.9       | 66.7 ± 6.2  | 115                               | 115                  |
| Cascalheira et al. (2015)           | 75.1 ± 3.1       | 71.0 ± 3.0  | 27                                | 28                   |
| Zhong et al. (2016)*                | 69.65 ± 8.63     | 71.24 ± 6.58| 27                                | 23                   |
| Zhong et al. (2016)**               | 70.55 ± 8.36     | 70.28 ± 7.25| 31                                | 31                   |
| Moretti et al. (2017)               | 77.9 ± 2.01      | 76.4 ± 2.3  | 86                                | 567                  |
| Ma et al. (2017)                    | 74.62 ± 8.01     | 72.82 ± 8.87| 89                                | 115                  |

*Altitude 3,380 m; **Altitude 2,260 m.*
American countries (10 publications), and Oceania countries (2 publications), respectively.

Each subgroup of the analysis was considered as an independent study according to the methods previously used (Moazzen et al., 2018). In total, 52 cross-section studies, 14 case-control studies, and 16 cohort studies were included for meta-analysis. The sample size ranged from 24 to 965.

**FIGURE 2** | SMD analysis of the plasma/serum folate levels between AD and controls. (A) Pooled estimate of SMD and 95% CI of folate levels among AD patients and controls; (B) Funnel plot for publication bias of SMD.
The Level of Plasma/Serum Folate Is Lower in AD Patients: Results From Cross-Sectional Studies

Fifty-two cross-sectional studies covering a total of 3,496 AD patients and 4,318 controls were included in the meta-analysis. The summary of these studies is shown in Table 1. The level of plasma/serum folate was lower in AD patients than that in the controls, with an SMD of $-0.60$ (95% CI: $-0.65$, $-0.55$) (Figure 2A).

The funnel plots appeared to be asymmetrical (Figure 2B). Moreover, Egger's test was performed. The $P$-value was 0.004, indicating there was potential publication bias across all included studies.

Folate Deficiency/Possible Deficiency Is Associated With the Risk for AD: Results From Case-Control Studies

Fifteen case-control studies involving 971 AD patients and 1,059 controls were included in the meta-analysis (Table 2). The sample size ranged from 27 to 181. Eight studies were conducted in European countries and seven studies were conducted in Asian countries.

The combined OR was 0.96 with 95% CI (0.93, 0.99) (Figure 3A). According to the level of plasma/serum folate, all individuals were further divided into two subgroups, folate deficiency/possible deficiency group and normal group with folate level $<13.5$ and $\geq 13.5$ nmol/L, respectively (WHO, 2015). In the folate deficiency/possible deficiency group, the combined OR was 1.94 (95% CI: 1.02, 2.86) (Figure 3B). However, the combined OR was 0.86 (95% CI: 0.46, 1.26) in the normal group (Figure 3B). The above data indicated that folate deficiency/possible deficiency is correlated with AD risk. It suggested that folate deficiency/possible deficiency may increase the risk for AD.

The funnel plots appeared to be symmetrical and all studies were within the 95% CIs, visually indicating there was no publication bias (Figures 3C–E). An Egger’s test was further performed to evaluate publication bias. The $P$-value was 0.011 in all studies, indicating there was publication bias, language bias, inflated estimates, and/or a lack of publications with opposite results. Moreover, the $P$-value was 0.957 in the subgroup of folate deficiency/possible deficiency, indicating there was no publication bias in this subgroup.

Folate Deficiency/Possible Deficiency Increases the Risk for AD: Results From Cohort Studies

Five studies from 2001 to 2017 were included in the meta-analysis (Table 3). Sample size ranged from 190 to 816. Two studies were conducted in Canada, and three in Italy, Sweden, and Switzerland, respectively. All the cohort studies presenting the folate levels of participants were divided into the folate deficiency/possible deficiency group and the normal group with folate level $<13.5$ and $\geq 13.5$ nmol/L, respectively. In the folate deficiency/possible deficiency group, the combined RR was 1.88 (95% CI: 1.20, 2.57) (Figure 4A). The data indicated that folate deficiency/possible deficiency increases the risk for AD.

Publication bias was analyzed by funnel plots. The funnel plots appeared to be symmetrical and all studies were within

---

**Table 2** | Summary of studies regarding the association between folate level and the risk of AD in 14 case-control studies.

| Folate level (nmol/L) | References | Sample size | Mean age (years) | OR (95% CI) | Adjusted | NOS | Country |
|----------------------|------------|-------------|-----------------|-------------|----------|-----|---------|
| 13.5 inclusive       | Clarke et al., 1998 | 164 108 | 73.2 ± 8.6 72.8 ± 8.8 | 2.3 (1.40, 4.50)* | YES 6 UK |
|                     | Hogervorst and Smith, 2002 | 66 62 | 77 ± 8 76 ± 8 | 0.41 (0.18, 0.90) | NO 6 UK |
|                     | Anello et al., 2004 | 180 181 | 71.0 ± 6.6 69.5 ± 12.7 | 0.95 (0.91, 1.0) | NO 6 Italy |
|                     | Mansoori et al., 2014 | 80 120 | 66.3 ± 8.9 63.8 ± 8.2 | 2.4 (1.4, 4.5) | NO 6 India |
|                     | Cascalheira et al., 2015 | 28 27 | 75.1 ± 1.5 71.0 ± 1.5 | 0.98 (0.93, 1.04) | NO 8 Portugal |
|                     | Ma et al., 2017 | 89 115 | 74.62 ± 8.01 72.82 ± 8.87 | 2.04 (0.53, 6.71)* | YES 8 China |
| ≥13.5                | Clarke et al., 1998 | — — | — — | 0.7 (0.4, 1.5)** | YES 6 UK |
|                     | Clarke et al., 1998 | — — | — — | 1.0 (0.5, 1.7)** | YES 6 UK |
|                     | Quadri et al., 2004 | 74 55 | 79.1 ± 7.7 75.8 ± 8.5 | 2.1 (0.6, 6.8)* | YES 6 Switzerland |
|                     | Mizrahi et al., 2004 | 75 155 | 88 ± 7.0 76±7.0 | 1.3 (0.5, 3.7)* | NO 6 Israel |
|                     | Mizrahi et al., 2004 | — — | — — | 1.6 (0.6, 4.2)* | NO 6 Israel |
|                     | Kim et al., 2013 | 100 121 | 79.4 ± 6.8 71.4 ± 6.6 | 2.70 (1.22, 5.98) | YES 6 South Korea |
|                     | Chen et al., 2015 | 115 115 | 67.6 ± 7.9 66.7 ± 6.2 | 2.2 (0.9-5.5) | NO 8 China |
|                     | Ma et al., 2017 | — — | — — | 3.42 (1.15, 8.34)** | YES 8 China |

*Plasma folate ≤17.1 nmol/L; **plasma folate 17.2–24.2 nmol/L; ***plasma folate >24.2 nmol/L.

$^\dagger$Plasma folate 13.5–19.5 nmol/L; $^\ddagger$plasma folate < 13.5 nmol/L.

$^\dagger$Plasma folate 7.87–11.40 nmol/L; $^\ddagger$plasma folate ≤7.86 nmol/L.

$^\dagger$Plasma folate 6.80–15.90 nmol/L; $^\ddagger$plasma folate ≤6.60 nmol/L.

---
FIGURE 3 | Meta-analysis for the associations between folate levels and risk of AD. (A) Combined folate OR of AD patients; (B) Combined OR in the folate deficiency/possible deficiency group and normal group; (C) Funnel plot for publication bias of AD vs. control; (D) Funnel plot for publication bias of the folate deficiency/possible deficiency group; (E) Funnel plot for publication bias of the normal folate group.
TABLE 3 | Summary of studies regarding the association between folate level and the risk of AD in five cohort studies.

| Serum folate (nmol/L) | References | Sample size | Follow-up time (years) | RR (95% CI) | Adjusted | NOS | Country |
|-----------------------|------------|-------------|------------------------|-------------|-----------|-----|---------|
| <13.5                 | Wang et al., 2001 | 370         | 3                      | 1.7 (0.9, 3.2) | YES       | 6   | Sweden |
|                       | Maxwell et al., 2002 | 226         | 5                      | 2.17 (0.85, 5.53) | NO        | 6   | Canada |
|                       | Ravaglia et al., 2005 | 816         | 4                      | 1.98 (1.15, 3.40) | YES       | 6   | Italy  |
|                       | Middleton et al., 2007 | 233         | 5                      | 1.91 (0.89, 4.11) | YES       | 6   | Canada |
| ≥13.5                 | Quadri et al., 2005 | 190         | —                      | 1.8 (0.7, 4.5)  | YES       | 6   | Switzerland |

FIGURE 4 | Meta-analysis for the associations between folate levels and risk of AD in general population. (A) Combined RR of AD in the folate deficiency/possible deficiency group; (B) Funnel plot for publication bias.

TABLE 4 | Summary of studies regarding the association between folate intake and the risk of AD in 11 cohort studies.

| Folate intake (µg/d) | References | Sample size | Statistical index | Follow-up time (years) | RR/HR (95% CI) | Adjusted | NOS | Country |
|----------------------|------------|-------------|-------------------|------------------------|----------------|----------|-----|---------|
| <400                 | Morris et al., 2006 | 205         | OR                | 3                      | 1.0 (0.4, 2.3)* | YES       | 6   | USA     |
|                      | Morris et al., 2006 | 221         | OR                | 3                      | 1.9 (0.7, 5.0)** | YES       | 6   | USA     |
|                      | Luchsinger et al., 2007 | 192         | HR                | 1.5                    | 0.9 (0.6, 1.3)* | YES       | 6   | USA     |
|                      | Corrada et al., 2005 | 203         | RR                | 9.3                    | 0.41 (0.22, 0.76) | YES       | 6   | USA     |
|                      | Morris et al., 2006 | 195         | OR                | 3                      | 2.7 (1.0, 7.1)*** | YES       | 6   | USA     |
|                      | Morris et al., 2006 | 210         | OR                | 3                      | 1.8 (0.5, 5.2)**** | YES       | 6   | USA     |
|                      | Luchsinger et al., 2007 | 192         | HR                | 1.5                    | 0.5 (0.3, 0.9)*** | YES       | 6   | USA     |
|                      | Nelson et al., 2009 | 727         | HR                | 9                      | 1.14 (0.71, 1.84) | YES       | 6   | USA     |
|                      | Nelson et al., 2009 | 727         | HR                | 9                      | 0.95 (0.54, 1.66)*** | YES       | 6   | USA     |
|                      | Nelson et al., 2009 | 727         | HR                | 9                      | 1.36 (0.68, 2.72)*** | YES       | 6   | USA     |
|                      | Nelson et al., 2009 | 726         | HR                | 9                      | 1.74 (0.80, 3.83)*** | YES       | 6   | USA     |

*Total folate intake 240–304 µg/d; **total folate intake 304–392 µg/d; ***total folate intake 392–620 µg/d; ****total folate intake 621–1,660 µg/d.

†Total folate intake ≤292.9 µg/d; ‡total folate intake ≥467.9 µg/d.

§Total folate intake 430 µg/d; §§total folate intake 476 µg/d; §§§total folate intake 524 µg/d; §§§§total folate intake 698 µg/d.
the 95% CIs, visually indicating there was no publication bias (Figure 4B).

**Sufficient Intake of Folate Reduces the Risk for AD: Results From Cohort Studies**

Eleven cohort studies published from 2005 to 2009 were included in the meta-analysis (Table 4). Sample size ranged from 192 to 727. All studies were conducted in the USA.

All the 11 cohort studies were included in the meta-analysis to examine the association between folate intake and AD in the elderly. The combined RR was 0.50 (95% CI: 0.25, 0.76). As the recommended daily allowance of folate is 400 µg, a daily intake of 400 µg of folate was used as the cut-off to define the two subgroups (Benoist, 2008). When the daily intake of folate was <400 µg, the combined RR and HR were 1.15 (95% CI: 0.28, 2.02) and 0.9 (95% CI: 0.6, 1.3), respectively (Figure 5A). When
the daily intake of folate was equal to or higher than 400 µg, the combined RR and HR were 0.44 (95% CI: 0.18, 0.71) and 0.76 (95% CI: 0.52, 0.99), respectively (Figures 5A,B). It indicated that sufficient folate intake (i.e., ≥400 µg/d) is a protective factor for AD, which significantly reduces the risk for AD.

Publication bias was analyzed by funnel plots. The funnel plots appeared to be symmetrical and all studies were within the 95% CIs, visually indicating there was no publication bias (Figures 5C–E).

**DISCUSSION**

The present analyses were designed to comprehensively evaluate the associations between AD and folate levels. The pooled results showed that the folate level of AD patients was lower compared with that of healthy controls. Moreover, the deficiency/possible deficiency of folate (<13.5 nmol/L) increases the risk for AD. Importantly, sufficient daily intake of folate (≥400 µg/d) reduces the risk of AD occurrence.

A meta-analysis was performed to explore the association between folate and Alzheimer's disease based on studies published before January, 2014 (Shen and Ji, 2015). Compared with the previous one, our study has the following distinguished characteristics. First, inclusion criteria of this study was restricted to AD, but not all forms of dementia. It might minimize the heterogeneity of different studies and make the conclusion more convincing. Moreover, cohort studies were included in addition to case-control studies. It indicated that folate deficiency/possible deficiency may have a causal effect on AD development. In addition, subgroup analysis was performed to evaluate the association between folate and AD. It definitely minimized the heterogeneity between the two populations, i.e., folate within normal range and folate deficiency/possible deficiency. Thus, our study highly indicated that folate deficiency/possible deficiency is a risk factor for AD. Importantly, the combined effect sizes of daily intake of folate and AD were first analyzed in this study. It indicated that sufficient daily intake of folate significantly reduces the risk for AD. Furthermore, the included studies were updated and cross-sectional studies were also included. For example, 52 cross-sectional studies covering 3,496 AD patients and 4,318 controls were included in the current study. The increase of the sample size makes the difference between AD and controls more reliable.

There were some limitations in this study. First, the different classification criteria, different categories of demographic characteristics, and different follow-up periods of the included studies may affect the pooled effects. Moreover, most of the studies were from North America, Europe, and Asia, with limited data from Africa and South America. The regional effect might need to be considered. Furthermore, more long-term follow-up studies were needed to confirm the preventive effect of sufficient folate intake on AD.

Although the mechanism of folate protecting against AD is not clear, there are plausible explanations for the association between AD and folate levels. First, folate has important biological activities, such as anti-oxidative stress, which counteracts AD development (Alonso et al., 2001; Agnati et al., 2007; De Felice et al., 2007; Zhang et al., 2009). Secondly, folate participates in the DNA methylation process as a donor of methyl, while DNA methylation plays a crucial role in aging and AD pathogenesis (Zhang et al., 2009; Smith and Lunnon, 2017). In addition, folate regulates the expression of both β-secretase and γ-secretase, these two key secretases contribute to Aβ generation and neuritic plaque formation (Fuso et al., 2007; Ly et al., 2013; Wang et al., 2017; Zhang et al., 2020). Moreover, folate inhibits tau phosphorylation and subsequent neurofibrillary tangle formation by indirectly regulating the activity of protein phosphatase cyclin-dependent kinase and glycogen synthase kinase (Sontag and Sontag, 2014). Furthermore, folate might also be implicated in AD by regulating the level of homocysteine (Hcy) as it is a co-factor of Hcy metabolism (Zhang et al., 2009; McCaddon and Miller, 2015; Smith and Refsum, 2016; Smith et al., 2018).

**CONCLUSIONS**

AD patients had lower levels of folate than healthy controls. Folate deficiency/possible deficiency may increase the risk for AD. Sufficient daily intake of folate may reduce the risk of AD occurrence. Trials have already shown that folic acid supplementation can slow cognitive decline and brain atrophy in patients with mild cognitive impairment (De Jager et al., 2012; Douaud et al., 2013; Ma et al., 2019). These findings indicated that sufficient folate intake is preventive against AD. Randomized controlled trials are needed to verify the causality of sufficient folate intake or folic acid supplementation and AD prevention.

**AUTHOR CONTRIBUTIONS**

YW designed the study. XZ, GB, and YY searched for and screened the literature. XZ, GB, and YY extracted the data independently. XZ, DL, GB, and YL conducted the meta-analysis constructions. XZ, GB, and YY analyzed the data and wrote this manuscript. XL, YL, and YW revised the manuscript. All authors reviewed and proved the manuscript.

**FUNDING**

This study was funded by the National Natural Science Foundation of China (NSFC) grant 81771147 to YW, grant 81901391 to YL, and grant 31701247 to XL.
REFERENCES

Abalain, F., Zittoun, J., Bouthami, C., Dugrais, G., Manciet, G., Decamps, A., et al. (1996). Plasma, red cell, and cerebrospinal fluid folate in Alzheimer's disease. Encephale 22, 430–434.

Agrawal, R., Chhiller, N., Kushwaha, S., Singh, N. K., and Tripathi, C. B. (2010). Role of vitamin B12, folate, and thyroid stimulating hormone in dementia: a hospital-based study in north Indian population. Ann. Indian Acad. Neural, 13, 257–262. doi: 10.4103/0972-2327.74193

Agnati, L. F., Genedani, S., Leo, G., Forni, A., Woods, A. S., Filarero, M., et al. (2007). Abeta peptides as one of the crucial volume transmission signals in the trophin units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer’s disease. J. Neural. Transm. 114, 21–31. doi: 10.1007/s00429-006-0056-4

Almeida, C. C., Brentani, H. P., Forlenza, O. V., and Diniz, B. S. (2011). Serum folic acid is reduced in patients with Alzheimer’s disease. Arch. Clin. Psychiatr. 39, 90–93. doi: 10.1093/acerp/npq034

Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2001). Abeta peptides as one of the crucial volume transmission signals in the trophin units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer’s disease. J. Neural. Transm. 114, 21–31. doi: 10.1007/s00429-006-0056-4

Anello, G., Guéant-Rodríguez, R.-M., Bosco, P., Guéant, J.-L., Romano, A., Fanelli, S., et al. (2012). Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int. J. Geriatr. Psychiatry 27, 592–600. doi: 10.1002/gps.2758

De Cager, C. A., Oulhaj, A., Jacoby, R., Refsum, H., and Smith, A. D. (2012). Reduced risk of Alzheimer’s disease with high folate intake: the Baltimore longitudinal study of aging. Alzheimers Dement. 1, 11–18. doi: 10.1016/j.jalz.2005.06.001

De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., et al. (2007). Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282, 11590–11601. doi: 10.1074/jbc.M607438200

REFERENCES

De Cager, C. A., Oulhaj, A., Jacoby, R., Refsum, H., and Smith, A. D. (2012). Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int. J. Geriatr. Psychiatry 27, 592–600. doi: 10.1002/gps.2758

De Lau, L. M., Refsum, H., Smith, A. D., Johnston, C., and Breteler, M. B. (2007). Plasma folate concentration and cognitive performance: Rotterdam Scan Study. J. Alzheimers Dis. 11, 275–290. doi: 10.3233/JAD-2006-9405

De Silva, H. A., Gunatilake, S. B., Johnston, C., Warden, D., and Smith, A. D. (2005). Medial temporal lobe atrophy, apolipoprotein genotype, and plasma homocysteine in Sri Lankan patients with Alzheimer’s disease. Exp. Aging Res. 31, 345–354. doi: 10.1080/03610730590948221

Dominguez, R. O., Marcheschi, E. R., Guareschi, E. M., Fumalari, A. L., Pagano, M. A., Serra, J. A., et al. (2005). Homocysteine, vitamin B12 and folate in Alzheimer’s and vascular dementia: the paradoxical effect of the superimposed type II diabetes mellitus condition. Clin. Chim. Acta 359, 163–170. doi: 10.1016/j.cjca.2005.03.049

Douaud, G., Refsum, H., De Cager, C. A., Jacoby, R., Nichols, T. E., Smith, M. S., and et al. (2013). Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl. Acad. Sci. U. S. A. 110, 9523–9528. doi: 10.1073/pnas.1301816110

Dunga, J., Boxtel, M. P. V., Schouten, E. G., Kok, F. J., Jolles, J., Katan, M. B., et al. (2007). Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369, 208–216. doi: 10.1016/S0140-6736(07)60109-3

Ebly, E. M., Schaefer, J. P., Campbell, N. R., and Hogan, D. B. (1998). Folate status, vascular disease and cognition in elderly Canadians. Age Ageing 27, 485–491. doi: 10.1093/ageing/27.4.485

Faux, N. G., Ellis, K. A., Porter, L., Fowler, C. J., Laws, S. M., Martins, R. N., et al. (2011). Homocysteine, vitamin B12, and folate acid levels in Alzheimer’s disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J. Alzheimers Dis. 27, 909–922. doi: 10.3233/JAD-2011-110752

Fioravanti, M., Ferrario, E., Massia, M., Cappa, G., Rivolta, G., Grossi, E., et al. (1997). Low folate levels in the cognitive decline of elderly patients and the efficacy of folate as a treatment for improving memory deficits. Arch. Gerontol. Geriatr. 26, 1–13. doi: 10.1016/S0167-4943(97)00028-9

Fuso, A., Cavallaro, R. A., Zampelli, A., D’Anselmi, F., and Scarpia, S. (2007). Gamma-Secretase is differentially modulated by alterations of homocysteine cycle in neuroblastoma and glioblastoma cells. J. Alzheimers Dis. 11, 275–290. doi: 10.3233/JAD-2007-11303

Galimberti, G., Conti, E., Zini, M., Piazza, F., Fenaroli, F., Isella, V., et al. (2008). Post-methionine load test: a more sensitive tool to reveal hyperhomocysteinemia in Alzheimer patients? Clin. Biochem. 41, 914–916. doi: 10.1016/j.clinbiochem.2008.03.015

Gallucci, M., Zanardo, A., De Valentin, L., and Vianello, A. (2004). Homocysteine in Alzheimer disease and vascular dementia. Arch. Gerontol. Geriatr. 38, 195–200. doi: 10.1016/j.archger.2004.04.027

Guo, J., Ni, S., Li, Q., Wang, J. Z., and Yang, Y. (2019). Folate/vitamin b alleviates hyperhomocysteinemia-induced Alzheimer-like pathologies in rat retina. Neurosci. Bull. 35, 325–335. doi: 10.1007/s12264-018-0293-9

Hagnelius, N. O., Wahlund, L. O., and Nilsson, T. K. (2008). CSF/folate serum folate gradient: physiology and determinants with special reference to dementia. Dement. Geriatr. Cogn. 25, 516–523. doi: 10.1159/000129966

Hassing, L., Wahlin, Winblad, B., and Bäckman, L. (1999). Further evidence on the effects of vitamin B12 and folate levels on episodic memory functioning: a
population-based study of healthy very old adults. Biol. Psychiat. 45, 1472–1480. doi: 10.1016/S0006-3223(98)00234-0

Hebert, L. E., Weuve, J., Scherr, P. A., and Evans, D. A. (2013). Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 80, 1778–1783. doi: 10.1212/WNL.0b013e31828726f5

Hegner, E., and Smith, A. D. (2002). The interaction of serum folate and estradiol levels in Alzheimer’s disease. Neuroendocrinol. Lett. 23, 155–160.

Hozo, S. P., Djulbegovic, B., and Hozo, I. (2005). Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 5:13. doi: 10.1186/1471-2288-5-13

Irizarry, M. C., Gurol, M. E., Raju, S., Diaz-Arrastia, R., Locascio, J. J., Tennis, D. S., et al. (2009). Homocysteine, vitamin B12 and cognitive behavior and psychological symptoms of Alzheimer’s disease. Am. J. Alzheimers Dis. 29, 38–44. doi: 10.1177/1533317510351011

Koseoglu, E., and Karaman, Y. (2007). Relations between homocysteine, folate and vitamin B12 on the level of estradiol in Alzheimer’s disease. Biol. Psychiat. 64, 86–92. doi: 10.1001/archneur.64.1.86

Leblhuber, F., Walli, J. S., Wagner-Jauregg, L.-N., Austria, L., Atner-Dworzak, M., et al. (2004). Folate and Alzheimer’s Disease. J. Neurol. 251, 1402–1408. doi: 10.1007/s00404-004-0357-9

Levitt, A. J., and Karlinsky, H. (1992). Folate, vitamin B12 and cognitive pathology and genomic expression profiles in the 3xTg-AD mice model. FASEB J. 30. Abstract retrieved from Abstracts in Embase (Embase Identification Number (PUI) L72319904).

Linnebank, M., Popp, J., Smulders, Y., Smith, D., Semmler, A., Farkas, B., et al. (2007). Serum folate concentrations in patients with cortical and subcortical dementia diagnosis. J. Neurol. 254, 76–79. doi: 10.1007/s00404-007-0586-9

Liu, C., Wei, Q., Liu, F. F., Hu, F., Xie, A. J., Zhu, L. Q., et al. (2018). Synthetic dysfunction in Alzheimer’s Disease: Aβ, tau, and epigenetic alterations. Mol. Neurobiol. 55, 3021–3032. doi: 10.1007/s12031-017-0536-3

Li, Q., Chen, Z., Zhang, S.-Z., Ma, L., Zhang, L., Wu, H., et al. (2014). Change of plasma levels hemocysteine and folate and vitamin B12 levels in mild cognitive impairment and Alzheimer’s Disease: a case-control study. Nutrients 9:725. doi: 10.3390/nu9070725

Malaguarnera, M., Ferri, R., Bellu, A., Alagona, G., Carnemolla, A., and Pennisi, G. (2004a). Helicobacter pylori and Alzheimer’s disease: a possible link. Eur. J. Intern. Med. 15, 381–386. doi: 10.1016/j.ejim.2004.05.008

Mansoori, N., Tripathi, M., Alam, R., Luthra, K., Sharma, S., Lakshmy, R., et al. (2014). Serum folate acid and RFC A80G polymorphism in Alzheimer’s disease and vascular dementia. Ann. J. Alzheimers Dis. 29, 38–44. doi: 10.1177/1533317513505131

McArdle, A., and Miller, J. W. (2015). Assessing the association between homocysteine and cognition: reflections on Bradford Hill, meta-analyses, and causality. Nutr. Rev. 73, 723–735. doi: 10.1093/nutrit/nvu022

Mclroy, S. P., Dyanan, K. B., Lawson, J. T., Patterson, C. C., and Passmore, A. P. (2002). Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, dementia, and Alzheimer disease in Northern Ireland. Stroke 33, 2351–2356. doi: 10.1161/01.STR.0000023550.90046.38

Mizrahi, E. H., Bowirrat, A., Jacobsen, D. W., Korczyn, A. D., Trofare, F., Petot, G. J., et al. (2004). Plasma homocysteine, vitamin B12 and folate in Alzheimer’s patients and healthy Arabs in Israel. J. Neurol. 227, 109–113. doi: 10.1016/j.jns.2004.08.011

Moazzzen, S., Dolatkhah, R., Tabrizi, J. S., Shaarabah, E., Alizadeh, B. Z., De Bock, G. H., et al. (2018). Folic acid intake and folate status and colorectal cancer risk: a systematic review and meta-analysis. Clin. Nutr. 37, 1926–1934. doi: 10.1016/j.clnut.2017.10.010

Morrell, R., Caruso, P., Dal Ben, M., Conti, C., Gazzin, S., and Tiribelli, C. (2017). Vitamin D, homocysteine, and folate in subcortical vascular dementia and Alzheimer dementia. Front. Aging Neurosci. 9:169. doi: 10.3389/fnagi.2017.00169

Morillas-Ruiz, J. M., Rubio-Perez, J. M., Albaladejo, M. D., Zafirr, P., Parra, S., and Vidal-Guevara, M. L. (2010). Effect of an antioxidant drink on homocysteine levels in Alzheimer’s patients. J. Neurol. 299, 175–178. doi: 10.1007/s00404-2010-0850-y

Morriss, M. S. (2003). Homocysteine and Alzheimer’s disease. Lancet Neurol. 2, 425–428. doi: 10.1016/S1474-4225(03)00438-1

Nelson, C., Wengreen, H. J., Munger, R. G., and Corcoran, C. D. (2009). Dietary folic acid and vitamin B-12 and B-6 not associated with incident Alzheimer’s disease. J. Alzheimers Dis. 9, 435–443. doi: 10.3233/JAD-2006-9410

Nurk, E., Refsum, H., Tell, G. S., Engedal, K., Vollset, S. E., Ueland, P. M., et al. (2005). Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Ann. Neurosci. 58, 487–857. doi: 10.1002/ana.20645

Pennisi, G. E., Vrecko, K., et al. (2000). Hyperhomocysteinemia in dementia. J. Neural Transm. 107, 1469–1474. doi: 10.1007/s007020070010

Rockwood, K. (2007). Exercise: a potential contributing factor to the relationship between folate and dementia. J. Am. Geriatr. Soc. 55, 1095–1098. doi: 10.1111/j.1532-5415.2007.01238.x

Silva, J. E., Viana, H. M., Cunha, C. A., Vieira, E. A., Moraes, J. A., et al. (2004). Homocysteine, vitamin B12 and folate in vascular dementia and Alzheimer disease. Braz. J. Med. Biol. Res. 37, 1926–1934. doi: 10.1590/S0100-879X2004000900008

Sims, R., and Vidal-Guevara, M. L. (2010). Effect of an antioxidant drink on plasma homocysteine in elderly people. J. Neurol. Sci. 299, 175–178. doi: 10.1016/j.jns.2010.08.050

Van de Putte, L., Klaassen, S., Meuleman, H., Yardimci, O., and Van Duijnhoven, F. J. (2004). Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 113, 224–235. doi: 10.1172/JCI26516

Wang, R., Zhou, H., Kim, S. Y., Tamura, T., et al. (2013). Association of serum folate and vitamin b12 levels in mild cognitive impairment and Alzheimer’s Disease: a case-control study. Nutrients 9:725. doi: 10.3390/nu9070725

Wu, H., Yu, Y., Zhou, Z., Wang, R., Wang, X., and Xie, Y. (2017). Folate and vitamin B12 levels in vascular dementia patients. Eur. J. Intern. Med. 38–39. doi: 10.1016/j.ejim.2017.01.012

Xu, H., and Li, G. (2007). Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clin. Chem. Lab. Med. 45, 1472–1480. doi: 10.1515/CCLM.2004.208
Otaegui-Arrazola, A., Amiano, P., Elbasto, A., Urbandeta, E., and Martinez-Lage, P. (2014). Diet, cognition, and Alzheimer's disease: food for thought. *Eur. J. Nutr.* 53, 1–23. doi: 10.1007/s00394-013-0561-3

Parnetti, L., Mecocci, P., Reboldi, G. P., Santucci, C., Brunetti, M., Gaiti, A., et al. (1992). Platelet MAO-B activity and vitamin B12 in old age dementias. *Mol. Chem. Neuropathol.* 16, 23–32. doi: 10.1007/BF01359938

Peng, H., Li, F.-M., and Ye, N. (2004). Correlations of Alzheimer disease with vitamin B12 and homocysteine. *Chin. J. Clin. Rehabil.* 8, 6210–6211. doi: 10.3321/j.issn:1673-8225.2004.28.030

Postiglione, A., Milan, G., Ruocco, A., Gallotta, G., Guiotto, G., and Di Minno, G. (2001). Plasma folate, vitamin B12, and total homocysteine and homocysteinylosis for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. *Gerontology* 47, 324–329. doi: 10.1159/000052822

Quadri, P., Fragiacomo, C., Pezzati, R., Zanda, E., Forloni, G., Tettamanti, M., et al. (2004). Homocysteine, folate, and vitamin B12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. *Am. J. Clin. Nutr.* 80, 114–122. doi: 10.1093/ajcn/80.1.114

Quadri, P., Fragiacomo, C., Pezzati, R., Zanda, E., Tettamanti, M., and Luca, U. (2005). Homocysteine and B vitamins in mild cognitive impairment and dementia. *Clin. Chem. Lab. Med.* 43, 1096–1100. doi: 10.1515/CCLM.2005.191

Ravaglia, G., Forti, P., Maioli, F., Bianchi, G., Martelli, M., Talercio, T., et al. (2004). Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. *Am. J. Clin. Nutr.* 80, 483–488. doi: 10.1093/ajcn/80.2.483

Ravaglia, G., Forti, P., Maioli, F., Vettori, C., Grossi, G., Bargossi, A. M., et al. (2001). Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment. *Mech. Ageing Dev.* 121, 251–261. doi: 10.1016/S0047-6374(00)00221-9

Ravaglia, G., Paola, F., Fabiola, M., Mabel, M., Lucia, S., Nicoletta, B., et al. (2005). Homocysteine and folate as risk factors for dementia and Alzheimer disease. *Am. J. Clin. Nutr.* 82, 636–643. doi: 10.1093/ajcn/82.3.636

Regland, B., Abrahamsson, L., Blennow, K., Gottfries, C. G., and Wallin, A. (1992). Vitamin B12 in CSF: reduced CSF/serum B12 ratio in demented men. *Acta Neurol. Scand.* 85, 276–281. doi: 10.1111/j.1600-0404.1992.tb04044.x

Religa, D., Styczynska, M., Peplonska, B., Gabryelewicz, T., Pfeffer, A., Chodakowska, M., et al. (2003). Homocysteine, apolipoprotein E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. *Dement. Geriatr. Cogn. Dis.* 16, 64–70. doi: 10.1159/000070677

Robinson, N., Grabowski, P., and Rehman, I. (2018). Alzheimer's disease pathogenesis: is there a role for folate? *Mech. Ageing Dev.* 174, 86–94. doi: 10.1016/j.mad.2017.10.001

Selley, M. L., Closea, D. R., and Sternh, S. E. (2002). The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. *Neurobiol. Aging* 23, 383–388. doi: 10.1016/S0197-4580(01)00327-X

Serot, J. M., Christmann, D., Dubost, T., Béné, M. C., and Faure, G. C. (2001). CSF-folate levels are decreased in late-onset AD patients. *J. Neural Transm.* 108, 93–99. doi: 10.1007/s007020017001

Shen, L., and Ji, H. F. (2015). Associations between homocysteine, folate acid, vitamin B12 and Alzheimer's disease: insights from meta-analyses. *J. Alzheimers Dis.* 46, 777–790. doi: 10.3233/JAD-150140

Smith, A. D., and Refsum, H. (2016). Homocysteine, B vitamins, and cognitive impairment. *Ann. Rev. Nutr.* 36, 211–239. doi: 10.1146/annurev-nutr-071715-050947

Smith, A. D., Refsum, H., Bottiglieri, T., Fenech, M., Hooshmand, B., McCaddon, A., et al. (2018). Homocysteine and dementia: an international consensus statement. *J. Alzheimers Dis.* 62, 561–570. doi: 10.3233/JAD-171042

Smith, R. G., and Lunnon, K. (2017). DNA modifications and Alzheimer’s disease. *Adv. Exp. Med. Biol.* 978, 303–319. doi: 10.1007/978-3-319-53889-1_16

Zhang, S., Cai, F., Wu, Y., Bozorgmehr, T., Wang, Z., Huang, D., et al. (2020). Homocysteine and folate status in subjects with and without Alzheimer's disease. *Eur. J. Nutr.* 60, 1509–1521. doi: 10.1007/s00394-020-02287-x

Zhang et al. Folate and Alzheimer's Disease

 conflicts of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Bao, Liu, Yang, Li, Cai, Liu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Copyright © 2021 Zhang, Bao, Liu, Yang, Li, Cai, Liu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.